Cellular Immunology & Immunotherapeutics

Editorial Panel

Michael G. Hanna
Founder & Chairman Emeritus
Vaccinogen, Inc.
USA

BiographyDr. Michael G Hanna, Jr. received his PhD in experimental pathology and immunology from the University of Tennessee (TN, USA) in the 1960s. He was a consultant with NASA for the lunar receiving laboratory during Apollo 11 and 12, for which his expertise in immunology was used in the testing of the lunar core powder for immunogenic or pathogenic materials. Dr. Hanna served during 1974–83 as Director of the National Cancer Institute, Frederick Cancer Research Center (MD, USA). He was Chief Operating Officer during 1985–94 of Organon Teknika/Biotechnology Research Institute and Senior Vice President of Organon Teknika Corporation, a subsidiary of Akzo Nobel, Netherlands. He developed and obtained approvals for TI CE BCG for the treatment of carcinoma in situ (CIS) bladder cancer, which remains the standard of care for prophylaxis of recurrence of superficial bladder cancer and therapy of CIS. Subsequently, Dr. Hanna founded PerImmune Inc., for which he served as President and Chief Executive Officer before it merged with Intracel Corp. in 1998. He continued to work for Intracel Resources as Chief Scientific Officer and Chairman. In 2007, Dr. Hanna founded Vaccinogen Inc., where he served as Chairman and CEO. Currently, Dr. Hanna is Chairman Emeritus. The company is a pioneer in the field of cancer vaccines and is developing OncoVAX, an autologous vaccine designed to elicit a specific immune response against cancer cells. The Phase 3 vaccine is being investigated for treatment mainly of colon cancer, but also for melanoma and renal cell carcinoma. In addition to cancer therapy research and development, Dr. Hanna has been involved in Homeland Security. He served as Chairman of the Department of Commerce Biotechnology Advisory Committee (1984–9) and also participated in the Department of Defense Technical Working Group for Biotechnology (1988–9). PerImmune completed a Department of Defense contract to manufacture the current effective therapeutic for Botulinum toxin, an equine heptavalent anti-toxin. Dr Hanna's research resulted in over 225 publications in international peer-reviewed journals and book chapters, and he holds 10 patents related to immunotherapy. Dr Hanna has been the recipient of numerous honors and awards and has served on many editorial boards, including for Human Vaccines & Immunotherapeutics.
Jagat R Kanwar
Professor
Centre for Molecular and Medical Research (C-MMR)
Deakin University
Australia

BiographyProfessor Jagat R Kanwar is the Head and team leader of Nanomedicine-Laboratory of Immunology and Molecular Biomedical Research (NLIMBR), School of Medicine, Faculty of Health, Deakin University, Australia. Professor Kanwar has an international reputation and expertise in investigating fundamental and applied molecular signalling aspects of pathogenesis of cancer, chronic inflammation and neurodegenerative diseases, thereby, leading to the development of treatment strategies from bench to bedside. He has more than 150 research publications in high impact factor and peer reviewed international journals, 27 book chapters and 3 edited books. Prof Kanwar's research has generated several patents/PCTs with more than five licensed patents for commercialization to BioPharma industry. His group is currently working on drug discovery and nanomedicine for oral and systemic drug delivery of a range of natural bioactive and biomacromolecules (proteins/peptides, siRNAs and aptamers) for targeting survivin, HIF-1α and other apoptotic and inflammatory cell signalling molecules in cancer, chronic inflammation and neurodegenerative disorders. His research combines Immunology with state of the art and cutting edge techniques in Molecular Biology, Biochemistry, Nanobiotechnology and visualization to investigate the pathways in which key molecules are regulated in both normal and disease states. A number of in vitro human cell/tissue based co-culture models for cancers, microbial infections; autoimmune diseases; chronic inflammatory diseases (osteoarthritis, inflammatory bowel disease), gut health, neurodegeneration and immunomodulation have been developed by his group. Kanwar's main research objective is to understand and target the mechanisms involved at the molecular and sub cellular level which gives us an edge over the prevalent targeting techniques. He carries out both academic and commercial research projects and develops new approaches for the diagnosis, treatment, and nanomedicine based new generation delivery systems. His recent research focus on locked nucleic acid (LNA) LNA-modified aptamers conjugated "double targeted nano-bullet nanocapsules" with natural anti-tumour proteins which specifically target cancer cells.
Armand Bensussan
Director
INSERM
Universite Paris Diderot
France

BiographyArmand Bensussan began his scientific career in the research laboratory Dausset at St. Louis hospital, before his training in the United States, at Harvard Medical School in Boston in the field of immuno-oncology. His major work, combining fundamentalist immunologists, biologists and dermatologists hospital clinicians, cover all the thematic under immuno-oncology dermatology, skin chronic inflammation and tissue regeneration. His INSERM unit, located first at the Henri-Mondor hospital in Creteil, is since 2009 on the site of the Saint-Louis Hospital. His research aims to define and identify, by combining molecular, functional and genetic approaches, diagnostic and therapeutic targets for diseases of the skin. With its employees, research concerning: the identification and characterization of membrane receptors and signaling of anomalies in skin tumors (T-cell lymphoma and melanoma), and extranodal (NK lymphomas / nasal T); identification and study of the functions of cell populations present in severe drug reactions and other inflammatory skin diseases such as psoriasis; the molecular and functional identification of specific receptors in lymphocyte subpopulations in healthy individuals (CD100 and CD101). With colleagues, they, for example, highlighted unique expression of KIR3DL2 receptor on the surface of primary cutaneous T-cell lymphomas, particularly, Sezary syndrome, erythroderma poor prognosis, since the median survival of patients is of about five years. This enabled them to demonstrate that this receptor was implicated in the pathophysiology of tumor and was a therapeutic target, thanks to the use of a specific monoclonal antibody they developed in partnership with Innate Pharma. Similarly, the study of signaling pathways that are involved in the proliferation of melanoma allowed Armand Bensussan and colleagues propose a novel therapeutic approach tested in an animal model, and to search for new genetic markers of susceptibility to melanoma. With regard to psoriasis, they are studying the role of regulatory T cells, which strongly express the CD39 membrane ecto-nucleotidase, and the mast cells which express CD160, a receptor specific molecules of class I major histocompatibility complex, they initially identified on the surface of NK cells (Natural Killer). Furthermore, they demonstrated that CD160 is also expressed by endothelial cells only when they are activated, corresponding to an anti-angiogenic therapeutic target. The theme of tissue regeneration that the laboratory develops treatment Burn Center at Saint Louis Hospital should lead Bensussan Armand and his staff to identify phenotypic markers of keratinocyte stem cell that will allow their order to isolate to study its differentiation and its interaction with innate immunity.
Alaa Ahmed
Chief Scientific Officer
Medical Research Center
KSA

Nafees Ahmad
Director, Immunity and Infection
Department of Immunobiology
The University of Arizona Health Sciences Center
USA

George F. Babcock
Associate Professor of Surgery
University of Cincinnati
USA

BiographyDr. George F. Babcock began his career at the University of Cincinnati, College of Medicine in 1983. Prior to coming to Cincinnati he received his B.S. from Muskingum University in New Concord, OH, his M.S. from North Dakota State University in Fargo, ND and his PhD from the University of Nebraska, College of Medicine, in Omaha NE in the laboratory of Dr. Robert McCarthy. His postdoctoral training was performed at the University of North Carolina in the laboratory of Dr. Geoffrey Haughton. Dr. Babcock began his professional career at The University of Texas System Cancer Center M.D. Anderson Hospital and Tumor Institute in Houston, Tx as an assistant professor. At the University of Cincinnati he joined the department of surgery rising to full professor, his current position. Dr. Babcock began at UC in the transplantation division and later move to the burn surgery division, now the division of plastic and burn surgery. He served as director of the department's graduate program in surgery until it was discontinued in the early 2000's. Currently Dr. Babcock is chair of UC's Institutional Animal Care and Use Committee (IACUC) and serves on the Institutional Biosafety Committee. In addition, Dr. Babcock is also the Deputy Director for Research at Shriners Hospitals for Children-Cincinnati, OH. He has participated in the teaching of several courses including Introduction to Immunology, Immunobiology of Diseases, Molecular Biology of the Cell III, Introduction to Biology, Analysis of Current Literature and Research in Nutrition, and the Veterinary Technology Program. Dr. Babcock has been on the editorial board of seven journals and additionally has reviewed manuscripts for 26 other journals. He is an active researcher with over 180 peer reviewed papers, 17 book chapters, and the series editor for 4 books and the edition editor for 1. Dr. Babcock has presented over 215 abstracts both submitted and invited. He is a member of 17 professional societies. He has been continuously funded during his tenure at UC including grants for NIH, DOD, Shriners of North America, the department of the Navy, the department of the Army and several biotechnology companies. He has served on NIH and DOD study sections and is currently the chair of the Military Infectious Diseases Research Program (MIDRP) study section, and is a consultant for NIH functioning as moderator for Office of Laboratory Animal Welfare (OLAW). His general research interests include Immunology, Microbiology and Inflammation. More specifically his research over the years has centered on cancer immunotherapy, transplantation immunology, the effects of burns and other trauma on the immune response with an emphasis on the innate immune system. Related to this is an interest in the regulation of apoptosis and adhesion molecules in neutrophils especially after burn trauma. The onset of infections and alterations in wound healing following thermal injury are also being investigated. In addition, area of research include the development of treatments for infected burn wounds especially the use of new anti-microbial agents and the use of biological response modifiers, research into modulation of the immune system by microvesicles and by nutritional manipulation of the host following burn injury, an examination of the immunotoxicolgy of agents encountered in the environment and the development and use of flow and image cytometry to measure biological responses.
Quentin Li
National Cancer Institute
National Institutes of Health
USA

Chi-Chiang Yang
Professor
School of Medical Laboratory and Biotechnology
Chung Shan Medical University
Taiwan

Udai Singh
Research Associate Professor
University of South Carolina
USA

Research InterestMy primary research interest includes in the area of immunology, mucosal inflammation, chemokines, immunotherapy and complimentary and alternative medicine. Inflammatory bowel disease (IBD) is a gastrointestinal disease of chronic inflammatory condition and the causes of human IBD remain unknown. We have shown that anti-CXCL10 Ab treatment abrogates spontaneous colitis. Currently, I am working on to understand the steps during CXCL10 mediated cellular and molecular mechanism of IBD abrogation and host immune response during the progression of IBD. This will help to better understand the pathogenesis of IBD and other inflammatory conditions. This work will contribute to a better understanding of autoimmune disease pathogenesis and the development of vaccines for inflammation therapeutics in general. Currently, I am working on intervention and prevention strategies against interstitial cystitis (IC), which is a chronic, relapsing and severely debilitating disease of the urinary bladder. Compounding these problems is the lack of blood or urine tests and consistently effective treatments for IC. We show the increase in CXCR3 ligands in the serum of IC patient as compare to normal healthy donors. We show for the first time that, CXCL10, CXCL9, and CXCL11 are significantly up regulated both systemic as well mucosal in IC patients, compared to normal healthy donors. These studies have important implications for the design, assessment, and implementation of effective IC diagnosis, intervention and prevention strategies. I am also working on another project to examine the effects of resveratrol on experimental murine model of colitis. We have shown that resveratrol protects against chronic and dextran sodium sulphate (DSS) induced colitis by inducing myeloid derived suppressor cells (MDSCs), down regulating mucosal and systemic effectors and CD4+T cells that express CXCR3+ expression. I wish to continue my work in the field of mucosal immunology, inflammation using alternative medicine as effective treatment for various autoimmune diseases and inflammation in general.
QI Wei
Associate Professor
Huazhong University of Science &Technology
China

Tigran Davtyan
Head of Analytical Laboratory
Scientific Centre of Drug and Medical Technology
Republic of Armenia

Arunava Bandyopadhaya
Postdoctoral fellow
Harvard Medical School
USA